Literature DB >> 2741196

A high-performance liquid chromatographic method for the measurement of deferoxamine in body fluids.

A Tesoro1, J S Leeder, Y Bentur, J Klein, M Freedman, G Koren.   

Abstract

A high-performance liquid chromatography method for the analysis of deferoxamine (DFO) in 100 microliters of serum or plasma is described. The procedure involves the addition of the internal standard ciprofloxacin to the sample, followed by ultrafiltration to remove protein. The ultrafiltrate is then directly injected into the chromatography system. Separation is achieved using a reverse-phase mu Bondapak C18 column and a ternary solvent system (sodium phosphate:acetonitrile:methanol) running at 2.0 ml/min. Assay time is 10 min, and chromatograms show no interference from coadministered drugs during this period of time. Coefficients of variation were found to be less than 5%, and analytical recovery of DFO was 85%. Validation experiments in an experimental dog model and in patients with iron overload demonstrate that the method is appropriate for studying the pharmacokinetics of DFO in thalassemic patients receiving drug for the treatment of chronic iron overload.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2741196

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  2 in total

1.  Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate.

Authors:  Giovanna Rassu; Elena Soddu; Massimo Cossu; Antonio Brundu; Guido Cerri; Nicola Marchetti; Luca Ferraro; Raymond F Regan; Paolo Giunchedi; Elisabetta Gavini; Alessandro Dalpiaz
Journal:  J Control Release       Date:  2015-01-22       Impact factor: 9.776

Review 2.  Deferoxamine (desferrioxamine). New toxicities for an old drug.

Authors:  Y Bentur; M McGuigan; G Koren
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.